Chiron’s Adjuvant Could Quadruple Flu Vaccine Capacity, CEO Pien Says
This article was originally published in The Pink Sheet Daily
The firm will meet with FDA to determine the regulatory pathway for the MF59 adjuvant in 2006.
You may also be interested in...
Shareholder ValueAct Capital owns 5% of Chiron's shares and 9% of non-Novartis-owned shares.
Fluvirin flu vaccine production capacity for 2005-2006 will be lower than the previous estimate of 18 mil.-25 mil. doses due to a shortened production season, CEO Pien says.
Chiron received approval for its flu vaccine Sept. 14 after adequately addressing FDA's manufacturing concerns.